Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By |2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment.  Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...

Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By |2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease.   Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By |2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).  These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation.  TNF-alpha is an inflammatory cytokine ...

Nov 22 2021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

By |2021-11-21T20:32:25-05:00November 22nd, 2021|Investor News, News, Press Releases|0 Comments

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...

Go to Top